1. Home
  2. IMNM vs MAN Comparison

IMNM vs MAN Comparison

Compare IMNM & MAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$18.76

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo ManpowerGroup

MAN

ManpowerGroup

N/A

Current Price

$46.57

Market Cap

2.5B

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNM
MAN
Founded
2006
1948
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.5B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
IMNM
MAN
Price
$18.76
$46.57
Analyst Decision
Strong Buy
Hold
Analyst Count
17
12
Target Price
$35.13
★ $51.94
AVG Volume (30 Days)
★ 1.4M
893.7K
Earning Date
11-09-2026
10-15-2026
Dividend Yield
N/A
★ 3.13%
EPS Growth
★ 51.40
N/A
EPS
N/A
★ 1.89
Revenue
$6,941,000.00
★ $17,957,100,000.00
Revenue This Year
N/A
$6.51
Revenue Next Year
N/A
$3.29
P/E Ratio
★ N/A
$24.34
Revenue Growth
N/A
★ 0.58
52 Week Low
$16.41
$25.15
52 Week High
$30.06
$63.88

Technical Indicators

Market Signals
Indicator
IMNM
MAN
Relative Strength Index (RSI) 46.46 45.57
Support Level $17.18 $44.02
Resistance Level $23.30 $48.48
Average True Range (ATR) 1.39 1.57
MACD 0.20 0.43
Stochastic Oscillator 25.98 64.13

Price Performance

Historical Comparison
IMNM
MAN

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About MAN ManpowerGroup

ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.

Share on Social Networks: